3
Shared Docs
3
Same-Page
3 / 3
Mentions
atents from yesterday's IPR decisions & MYL confirming that the third IPR decision is expected by 1-Sept, our analyst Sumant has notes out on TEVA, MYL & MNTA walking through his assumptions/thoughts. For TEVA, while today's ruling is somewhat of a setback, I'd argue that risk/reward is still positive give
den of proof is on the generics). Also note that the traditional P-IV challenge from MNTA/Sandoz/MYL/Amneal/Synthon/PFE/DRRD will kick off 26-Sep. 4 Net/net, a victory for TEVA likely sees a 10%+ move higher in my view (S58ish) while a negative outcome likely sees 5% downside to around $50/sh (given
atents from yesterday's IPR decisions & MYL confirming that the third IPR decision is expected by 1-Sept, our analyst Sumant has notes out on TEVA, MYL & MNTA walking through his assumptions/thoughts. For TEVA, while today's ruling is somewhat of a setback, • argue that risk/reward is still positive given
rden of proof is on the generics). Also note that the traditional P-IV challenge from MNTA/Sandoz/MYL/AmneaUSynthon/PFE/DRRD will kick off 26-Sep. 4 Net/net, a victory for TEVA likely sees a 10%+ move higher in my view (S58ish) while a negative outcome likely sees 5% downside to around $50/sh (given
atents from yesterday's IPR decisions & MYL confirming that the third IPR decision is expected by 1-Sept, our analyst Sumant has notes out on TEVA, MYL & MNTA walking through his assumptions/thoughts. For TEVA, while today's ruling is somewhat of a setback, I'd argue that risk/reward is still positive give
den of proof is on the generics). Also note that the traditional P-IV challenge from MNTA/Sandoz/MYL/Amneal/Synthon/PFE/DRRD will kick off 26-Sep. 4 Net/net, a victory for TEVA likely sees a 10%+ move higher in my view (S58ish) while a negative outcome likely sees 5% downside to around $50/sh (given
Entities connected to both MYL & MNTA and 4 Net

Jeffrey Epstein
PERSON
Marc Rich
PERSONPierce, Fenner & Smith Incorporated
ORGANIZATIONAmanda
PERSON
Richard Kahn
PERSONMNTA/Sandoz/MYL
ORGANIZATIONCopaxone Litigation Timeline
ORGANIZATIONHealthcare Specialist Sales
ORGANIZATIONReddy
LOCATIONDaniel Lundquist
PERSONSumant
ORGANIZATIONSector Specialist Sales
ORGANIZATION
Mylan
ORGANIZATIONTEVVF Pfd
ORGANIZATIONCopaxone
ORGANIZATIONEpiPen
ORGANIZATIONSandoz/NVS
ORGANIZATIONMYL Note
ORGANIZATIONCopaxone 3TW Litigation
ORGANIZATIONCopaxone 3TW
ORGANIZATION